Identification

Name
Felodipine
Accession Number
DB01023  (APRD00374)
Type
Small Molecule
Groups
Approved, Investigational
Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure
Thumb
Synonyms
  • (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
  • 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
  • 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
  • Felodipina
  • Felodipine
  • Felodipinum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felodipineextended-release TabletsTablet, extended release10 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release2.5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
PlendilTablet, extended release2.5 mg/1OralAstra Zeneca Lp1994-10-042016-11-04Us
PlendilTablet, extended release10 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
PlendilTablet, extended release5 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
PlendilTablet, extended release10 mg/1Oralbryant ranch prepack1991-09-16Not applicableUs
Plendil 10 mgTablet, extended release10 mgOralAstra Zeneca1992-12-31Not applicableCanada
Plendil 2.5 mgTablet, extended release2.5 mgOralAstra Zeneca1994-12-31Not applicableCanada
Plendil 5 mgTablet, extended release5 mgOralAstra Zeneca1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-felodipineTablet, extended release5 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release2.5 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release10 mgOralApotex Corporation2016-04-22Not applicableCanada
FelodipineTablet, film coated, extended release2.5 mg/1OralAv Kare, Inc.2014-03-312016-01-15Us
FelodipineTablet, film coated, extended release2.5 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2010-12-20Not applicableUs68462 0233 01 nlmimage10 1e3e0f60
FelodipineTablet, film coated, extended release5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-16Not applicableUs
FelodipineTablet, film coated, extended release2.5 mg/1OralRichmond Pharmaceuticals2004-11-02Not applicableUs
FelodipineTablet, extended release10 mg/1OralA S Medication Solutions2011-11-282017-06-20Us
FelodipineTablet, extended release5 mg/1OralPar Pharmaceutical2011-12-15Not applicableUs
FelodipineTablet, film coated, extended release10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-19Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Altace Plus Felodipine 2.5mg + 2.5mgFelodipine (2.5 mg) + Ramipril (2.5 mg)TabletOralSanofi Aventis2006-06-272012-10-10Canada
Altace Plus Felodipine 5mg + 5mgFelodipine (5 mg) + Ramipril (5 mg)TabletOralSanofi Aventis2006-06-272012-10-15Canada
International/Other Brands
Felodur ER / Felogard / Penedil / Plendil Depottab (AstraZeneca) / Plendil ER (AstraZeneca) / Plendil Retard (AstraZeneca) / Splendil
Categories
UNII
OL961R6O2C
CAS number
72509-76-3
Weight
Average: 384.254
Monoisotopic: 383.069113515
Chemical Formula
C18H19Cl2NO4
InChI Key
RZTAMFZIAATZDJ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Associated Conditions
Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UCalmodulin
other
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UMineralocorticoid receptor
antagonist
Human
UTroponin C, skeletal muscle
other
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution
  • 10 L/kg
Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance
  • 0.8 L/min [Young healthy subjects]
Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Felodipine Metabolism PathwayDrug metabolism
Felodipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Felodipine.Experimental
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Felodipine.Experimental, Investigational
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Felodipine.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Felodipine.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Felodipine.Approved, Investigational
AceclofenacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Felodipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Felodipine.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Felodipine.Investigational
AlclofenacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumFelodipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Felodipine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Felodipine.Approved, Investigational
AliskirenFelodipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Felodipine.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololFelodipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Felodipine.Approved, Investigational
AmifostineFelodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.Approved
AminophenazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Felodipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Felodipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Felodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Felodipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Felodipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Felodipine.Approved
Amphotericin BFelodipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Felodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.Approved
AntipyrineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Apalutamide can be increased when it is combined with Felodipine.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Felodipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.Approved
AprepitantThe serum concentration of Felodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Felodipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Felodipine.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Felodipine.Approved, Nutraceutical
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Felodipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Felodipine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Felodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Felodipine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Felodipine.Approved
AtracuriumFelodipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Felodipine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Felodipine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Felodipine.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe metabolism of Balaglitazone can be decreased when combined with Felodipine.Investigational
BalsalazideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Felodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Felodipine.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Felodipine.Approved, Investigational
BarnidipineFelodipine may increase the antihypertensive activities of Barnidipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Felodipine.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Felodipine.Approved, Investigational
BenazeprilatFelodipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Felodipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Felodipine.Withdrawn
BenorilateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Benzydamine.Approved
BepridilFelodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Felodipine.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Felodipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Felodipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Felodipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Felodipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Felodipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Felodipine.Approved
BisoprololBisoprolol may increase the hypotensive activities of Felodipine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Felodipine.Approved
BoceprevirThe metabolism of Felodipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Felodipine.Approved, Investigational
BosentanThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.Approved
BQ-123Felodipine may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.Approved, Investigational
BretyliumFelodipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Felodipine.Approved, Investigational
BrigatinibThe serum concentration of Felodipine can be decreased when it is combined with Brigatinib.Approved, Investigational
BromfenacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Felodipine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Felodipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.Investigational
BufexamacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Felodipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felodipine.Approved, Investigational
BupranololFelodipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Felodipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Felodipine.Experimental
Calcium AcetateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Felodipine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Felodipine.Approved
CandesartanFelodipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Felodipine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Felodipine.Experimental
CaptoprilFelodipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Felodipine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Felodipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Felodipine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Felodipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Felodipine.Withdrawn
CarprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololFelodipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Felodipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Felodipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Felodipine.Approved, Investigational
CeritinibThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Felodipine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Felodipine.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Felodipine.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Felodipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Felodipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineFelodipine may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe metabolism of Ciglitazone can be decreased when combined with Felodipine.Experimental
CilazaprilFelodipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.Approved, Investigational
CimetidineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Cimicoxib.Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
CisatracuriumFelodipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Felodipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Felodipine.Approved
ClarithromycinThe metabolism of Felodipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Felodipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Felodipine.Approved
ClonixinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.Approved
CloranololFelodipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Felodipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Felodipine.Approved
CobicistatThe metabolism of Felodipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Felodipine.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Felodipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Felodipine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Felodipine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Felodipine.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Felodipine.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Felodipine.Approved
CurcuminThe metabolism of Felodipine can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideFelodipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Felodipine.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Felodipine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Felodipine.Approved
DabrafenibThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Felodipine.Approved, Investigational
DanazolThe metabolism of Felodipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Felodipine.Approved, Investigational, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Felodipine.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Felodipine.Approved
DarunavirThe metabolism of Felodipine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Felodipine.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Felodipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Felodipine.Approved, Investigational
DeferasiroxThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilFelodipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Felodipine can be decreased when combined with Delavirdine.Approved
DeserpidineFelodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.Approved, Vet Approved
DexniguldipineFelodipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Felodipine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Felodipine.Approved
DiclofenacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineFelodipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Felodipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Felodipine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Felodipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Felodipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Felodipine.Approved, Investigational
DiltiazemThe metabolism of Felodipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Felodipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Felodipine.Approved
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Felodipine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Felodipine.Approved
DoxacuriumFelodipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Felodipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Felodipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Felodipine.Approved, Investigational
DoxycyclineThe metabolism of Felodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Felodipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Felodipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Felodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.Approved
EfavirenzThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Felodipine.Approved
EfonidipineFelodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Felodipine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Felodipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Felodipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Felodipine.Approved, Vet Approved
EnalaprilatFelodipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Felodipine.Experimental
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Felodipine.Approved
EpanololFelodipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Felodipine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Felodipine can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Felodipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Felodipine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Felodipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Felodipine.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Felodipine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
EsatenololFelodipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololFelodipine may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Felodipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.Approved, Investigational
EthenzamideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.Approved
EtodolacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Felodipine.Approved
EtoricoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Felodipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Felodipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Felodipine.Approved
FelbinacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Felodipine.Approved
FenoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Felodipine.Experimental
FeprazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidFelodipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Felodipine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Felodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Felodipine.Approved
FluconazoleThe serum concentration of Felodipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Felodipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Felodipine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Felodipine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Felodipine.Experimental
FluvoxamineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Felodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Felodipine.Approved
FosinoprilatFelodipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Felodipine.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Felodipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineFelodipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideFelodipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Felodipine.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Felodipine.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Felodipine.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Felodipine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Felodipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Felodipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Felodipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Felodipine.Approved
GuanazodineFelodipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFelodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Felodipine.Approved, Investigational
GuanoclorFelodipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFelodipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFelodipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Felodipine.Experimental
HexamethoniumFelodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Felodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Felodipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Felodipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Felodipine resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Felodipine.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Felodipine.Approved
IbuprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Felodipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Felodipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Felodipine.Approved
IloprostIloprost may increase the hypotensive activities of Felodipine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Felodipine.Approved
ImidaprilFelodipine may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Felodipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Felodipine.Approved
IndenololFelodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Felodipine can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Felodipine.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Felodipine.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Felodipine.Withdrawn
IrbesartanFelodipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Felodipine.Approved, Investigational
IsavuconazoleThe serum concentration of Felodipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Felodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Felodipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Felodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Felodipine.Approved, Vet Approved
IsoniazidThe metabolism of Felodipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.Approved
IsoxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Felodipine.Approved, Investigational
ItraconazoleThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Felodipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Felodipine.Approved, Investigational
KebuzoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Felodipine.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Felodipine.Approved
KetoconazoleThe serum concentration of Felodipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Felodipine.Approved
LacidipineFelodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Felodipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Felodipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Felodipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Felodipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Felodipine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Felodipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Felodipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Felodipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Felodipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Felodipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Felodipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Felodipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felodipine.Approved, Investigational
LevodopaFelodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Felodipine.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Felodipine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Felodipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Felodipine.Approved, Investigational
LinsidomineFelodipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Felodipine.Approved, Investigational
LobeglitazoneThe metabolism of Lobeglitazone can be decreased when combined with Felodipine.Approved, Investigational
LofexidineFelodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Felodipine.Approved
LopinavirThe metabolism of Felodipine can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Felodipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Felodipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Felodipine.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Felodipine.Approved, Investigational
LuliconazoleThe serum concentration of Felodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Felodipine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Felodipine.Approved, Investigational
MacitentanFelodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Felodipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Felodipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Felodipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineFelodipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Felodipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Felodipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Felodipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Mefenamic acid.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Felodipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Felodipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Felodipine.Approved
MesalazineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Felodipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Felodipine.Approved
MethoserpidineFelodipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Felodipine.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Felodipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Felodipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Felodipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Felodipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Felodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Felodipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.Approved, Vet Approved
MetipranololFelodipine may increase the hypotensive activities of Metipranolol.Approved
MetocurineFelodipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideFelodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Felodipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Felodipine.Approved, Investigational
MetyrosineFelodipine may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Felodipine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Felodipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Felodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Felodipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Felodipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Felodipine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Felodipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Felodipine.Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Felodipine.Approved
MitotaneThe serum concentration of Felodipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.Approved, Investigational
MivacuriumFelodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Felodipine.Approved, Investigational
ModafinilThe serum concentration of Felodipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Felodipine.Approved
MofebutazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Felodipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Felodipine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Felodipine.Approved, Investigational
MuzolimineFelodipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.Approved, Investigational
NabumetoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Felodipine.Approved
NafcillinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilFelodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Felodipine.Approved
NaloxoneThe metabolism of Felodipine can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololFelodipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Felodipine.Approved, Withdrawn
NelfinavirThe metabolism of Felodipine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Felodipine.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.Approved, Investigational
NetoglitazoneThe metabolism of Netoglitazone can be decreased when combined with Felodipine.Experimental
NetupitantThe serum concentration of Felodipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Felodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Felodipine.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Felodipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Felodipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Felodipine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Felodipine.Approved
NifenazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Felodipine.Experimental
NilotinibThe metabolism of Felodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineFelodipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Felodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Felodipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Felodipine.Approved
NitrendipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Felodipine.Approved
NitroaspirinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.Approved, Investigational
NitroprussideFelodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Felodipine.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Felodipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Felodipine.Approved
NS-398The therapeutic efficacy of Felodipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabFelodipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Felodipine.Withdrawn
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Felodipine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Felodipine.Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Felodipine.Approved, Investigational
OlaparibThe metabolism of Felodipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Felodipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Felodipine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Felodipine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Felodipine.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Felodipine.Approved
OxaprozinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Felodipine.Approved
OxprenololFelodipine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Felodipine.Investigational, Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Felodipine.Approved, Vet Approved
PalbociclibThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Felodipine.Approved
PancuroniumFelodipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Felodipine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Felodipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Felodipine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Felodipine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Felodipine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.Approved
PenbutololFelodipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Felodipine.Experimental
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Felodipine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
PentoliniumFelodipine may increase the hypotensive activities of Pentolinium.Approved
PerindoprilPerindopril may increase the hypotensive activities of Felodipine.Approved
PerindoprilatFelodipine may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Felodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Felodipine.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Felodipine.Vet Approved
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Felodipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Felodipine.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Felodipine.Approved
PhenylbutazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Felodipine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Felodipine.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Felodipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Felodipine.Approved
PindololFelodipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Felodipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.Approved, Investigational
PipecuroniumFelodipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Felodipine.Approved
PiroxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Felodipine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Felodipine.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Felodipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Felodipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Felodipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Felodipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Felodipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Felodipine.Approved, Vet Approved
PolythiazideFelodipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Felodipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Felodipine.Approved, Investigational
PosaconazoleThe metabolism of Felodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Felodipine.Approved, Investigational
PractololFelodipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.Approved, Investigational
PranoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Felodipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Felodipine.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Felodipine.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Felodipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Felodipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Felodipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Felodipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Felodipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Felodipine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Felodipine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Felodipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Felodipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Felodipine.Approved, Investigational
QuinaprilatFelodipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Felodipine.Approved, Investigational
QuinineThe metabolism of Felodipine can be increased when combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Felodipine.Approved
RamiprilatFelodipine may increase the hypotensive activities of Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Felodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Felodipine.Approved, Investigational
RapacuroniumFelodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Felodipine.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Felodipine.Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Felodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Felodipine.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Felodipine.Approved, Investigational
RescinnamineFelodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Felodipine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Felodipine.Experimental
RibociclibThe serum concentration of Felodipine can be increased when it is combined with Ribociclib.Approved, Investigational
RifampicinThe metabolism of Felodipine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Felodipine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Felodipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Felodipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Felodipine.Approved, Investigational
RimexoloneThe metabolism of Felodipine can be increased when combined with Rimexolone.Approved
RiociguatFelodipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneFelodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Felodipine.Approved, Investigational
RituximabFelodipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.Approved
RivoglitazoneThe metabolism of Rivoglitazone can be decreased when combined with Felodipine.Experimental, Investigational
RobenacoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumFelodipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Felodipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felodipine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Felodipine.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Felodipine.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Felodipine.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Felodipine.Approved
SafinamideSafinamide may increase the hypotensive activities of Felodipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Felodipine.Withdrawn
SalicylamideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Salsalate.Approved
SaprisartanFelodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Felodipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Felodipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Felodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Felodipine.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Felodipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Felodipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felodipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Felodipine.Approved
SiltuximabThe serum concentration of Felodipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Felodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Felodipine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Felodipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Felodipine.Approved, Investigational
SitaxentanFelodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Felodipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Felodipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Felodipine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Felodipine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Felodipine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Felodipine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Felodipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Felodipine.Experimental
SpiraprilFelodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.Approved
St. John's WortThe serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Felodipine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Felodipine.Experimental
StiripentolThe serum concentration of Felodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Felodipine.Approved
SulfasalazineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sulindac.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Felodipine.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Felodipine.Approved, Investigational
SuprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Felodipine can be decreased when used in combination with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Felodipine.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Felodipine.Investigational
TalniflumateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Felodipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Felodipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Felodipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Felodipine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Felodipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Felodipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Felodipine.Approved, Investigational
TemocaprilFelodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.Approved
TenidapThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Felodipine.Approved
TenoxicamThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Felodipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Felodipine.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Felodipine.Approved, Withdrawn
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Felodipine.Approved, Vet Approved
TetrahydropalmatineFelodipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Felodipine.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Felodipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Felodipine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Felodipine.Approved
TicrynafenFelodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Felodipine.Approved
TinoridineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Felodipine.Approved
TipranavirThe metabolism of Felodipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.Approved, Investigational
TocilizumabThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneFelodipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Felodipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tolmetin.Approved
TolonidineFelodipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Felodipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Felodipine.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Felodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Felodipine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Felodipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Felodipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Felodipine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Felodipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Felodipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Felodipine.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Felodipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Felodipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Felodipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Felodipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Felodipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Felodipine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Felodipine.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Felodipine can be decreased when combined with Troleandomycin.Approved
TubocurarineFelodipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Felodipine.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Felodipine.Approved
UnoprostoneFelodipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Felodipine.Investigational
ValdecoxibThe therapeutic efficacy of Felodipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Felodipine.Experimental
ValsartanValsartan may increase the hypotensive activities of Felodipine.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Felodipine.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Felodipine.Approved
VecuroniumFelodipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Felodipine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Felodipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Felodipine.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Felodipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Felodipine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Felodipine.Approved
VincamineFelodipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Felodipine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Felodipine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Felodipine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Felodipine.Approved, Investigational
VoriconazoleThe metabolism of Felodipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Felodipine.Approved, Investigational
XipamideFelodipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Felodipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Felodipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Felodipine.Approved
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Felodipine.Approved
ZofenoprilFelodipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Felodipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Felodipine.Approved, Investigational
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061
General References
  1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737]
External Links
Human Metabolome Database
HMDB0015158
KEGG Drug
D00319
PubChem Compound
3333
PubChem Substance
46506968
ChemSpider
3216
BindingDB
189379
ChEBI
585948
ChEMBL
CHEMBL1480
Therapeutic Targets Database
DAP000487
PharmGKB
PA449591
IUPHAR
4190
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Felodipine
ATC Codes
C08CA02 — FelodipineC09BB05 — Ramipril and felodipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (228 KB)
MSDS
Download (55.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentFood-Drug Interactions1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4CompletedPreventionDisorders Related to Lung Transplantation1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Sexual Dysfunctions1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableUnknown StatusBasic ScienceHigh Blood Pressure (Hypertension) / Insulin Resistance / Microcirculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cardinal Health
  • Heartland Repack Services LLC
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Resource Optimization and Innovation LLC
  • Richmond Pharmacy
  • Sandhills Packaging Inc.
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral2.5 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral2.5 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral2.5 mg
Tablet, extended releaseOral5 mg
Prices
Unit descriptionCostUnit
Plendil 10 mg 24 Hour tablet3.17USD tablet
Plendil er 10 mg tablet3.05USD tablet
Plendil 10 mg tablet sa2.96USD tablet
Felodipine 10 mg 24 Hour tablet2.95USD tablet
Plendil er 2.5 mg tablet2.94USD tablet
Felodipine er 10 mg tablet2.72USD tablet
Plendil er 5 mg tablet2.6USD tablet
Plendil 5 mg 24 Hour tablet1.77USD tablet
Plendil 2.5 mg 24 Hour tablet1.76USD tablet
Felodipine 5 mg 24 Hour tablet1.67USD tablet
Plendil 2.5 mg tablet sa1.65USD tablet
Plendil 5 mg tablet sa1.65USD tablet
Felodipine 2.5 mg 24 Hour tablet1.57USD tablet
Felodipine er 2.5 mg tablet1.51USD tablet
Felodipine er 5 mg tablet1.51USD tablet
Renedil 10 mg Extended-Release Tablet1.22USD tablet
Plendil 10 mg Extended-Release Tablet1.15USD tablet
Renedil 5 mg Extended-Release Tablet0.81USD tablet
Plendil 5 mg Extended-Release Tablet0.77USD tablet
Sandoz Felodipine 10 mg Extended-Release Tablet0.73USD tablet
Renedil 2.5 mg Extended-Release Tablet0.6USD tablet
Plendil 2.5 mg Extended-Release Tablet0.57USD tablet
Sandoz Felodipine 5 mg Extended-Release Tablet0.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145 °CNot Available
water solubility19.7 mg/LNot Available
logP3.86SANGSTER (1994)
Caco2 permeability-4.64ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00715 mg/mLALOGPS
logP4.36ALOGPS
logP3.44ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)5.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.2 m3·mol-1ChemAxon
Polarizability38.04 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9878
Blood Brain Barrier-0.83
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5149
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8664
CYP450 2C9 substrateNon-substrate0.8357
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9304
Ames testNon AMES toxic0.7849
CarcinogenicityNon-carcinogens0.7511
BiodegradationNot ready biodegradable0.9527
Rat acute toxicity2.4526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udu-0139000000-085071c20c5d0c134d8f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds
show 5 more
Substituents
Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Johnson JD, Andrews CT, Khabbaza EJ, Mills JS: The interaction of felodipine with calcium-binding proteins. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S53-9. [PubMed:2442519]
  3. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  4. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
  5. Mills JS, Bailey BL, Johnson JD: Cooperativity among calmodulin's drug binding sites. Biochemistry. 1985 Aug 27;24(18):4897-902. [PubMed:4074665]
  6. Walsh MP, Sutherland C, Scott-Woo GC: Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes. Biochem Pharmacol. 1988 Apr 15;37(8):1569-80. [PubMed:2833901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Calcium ion binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC2
Uniprot ID
P02585
Uniprot Name
Troponin C, skeletal muscle
Molecular Weight
18121.895 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF: Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37. doi: 10.1074/jbc.M802180200. Epub 2008 Apr 15. [PubMed:18413310]
  2. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 12:25